Detailed characterization of aeration in lubricating oils by an ultrasonic approach
Che Zhan
,
Arnaud Saint-Jalmes
,
M. Receveur
,
H. El Bahi
,
F. Rondelez
et al.
Journal articles
hal-03739162v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey
A. Garioud
,
J. -F. Cadranel
,
A. Pauwels
,
T. Thevenot
,
A. Louvet
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S833, 2015,
⟨10.1016/S0168-8278(15)31461-6⟩
Conference poster
hal-01162774v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Daclatasvir plus Sofosbuvir with or without Ribavirin in Patients with HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate use Programme
V. Leroy
,
C. Hezode
,
S. Metivier
,
M. Tateo
,
F. Conti
et al.
Journal articles
hal-03590935v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
E. Rosenthal
,
C Fougerou-Leurent
,
A. Renault
,
Mp. Carrieri
,
F. Marcellin
et al.
Journal articles
hal-01740817v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Propagation of ultrasound in aqueous foams
Imen Ben Salem
,
Reine-Marie Guillermic
,
V. Leroy
,
Arnaud Saint-Jalmes
,
Benjamin Dollet
et al.
EUFOAM conference , Jul 2012, Lisbonne, Portugal
Conference papers
hal-00935761v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study
Jerome Dumortier
,
V. Leroy
,
C. Duvoux
,
V. De Lédinghen
,
C. Francoz
et al.
Journal articles
hal-01397762v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Outils connectés d’APA et cancer de la prostate : revue de la littérature et retour d’expérience
A. Corbel
,
V. Leroy
,
Q. Vesval
,
A. Rebillard
,
R Mathieu
et al.
Journal articles
hal-03886482v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
A. Coilly
,
C. Fougerou
,
V. de Ledinghen
,
P. Houssel-Debry
,
C. Duvoux
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. pp.S236--S237,
⟨10.1016/S0168-8278(15)30103-3⟩
Conference papers
hal-01162709v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study
J. Dumortier
,
D. Botta-Fridlund
,
A. Coilly
,
V. Leroy
,
C. Fougerou-Leurent
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. pp.S247--S248,
⟨10.1016/S0168-8278(15)30128-8⟩
Conference papers
hal-01162706v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
LEDIPASVIR/SOFOSBUVIR IN NS3/4A PROTEASE INHIBITOR-EXPERIENCED SUBJECTS WITH HCV GENOTYPE 1 AND HIV-COINFECTION FINAL RESULTS OF THE ANRS HC31 SOFTRIH STUDY
E. Rosenthal
,
C. Fougerou-Leurent
,
A. Renault
,
E. Teicher
,
S. Dominguez
et al.
Journal of Hepatology , 2016, 64, pp.S764--S764
Journal articles
hal-01533344v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program
C. Hezode
,
V. de Ledinghen
,
H. Fontaine
,
F. Zoulim
,
P. Lebray
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S265--S266, 2015,
⟨10.1016/S0168-8278(15)30159-8⟩
Conference poster
hal-01162768v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study
T.M. Antonini
,
A. Coilly
,
E. Rossignol
,
C. Fougerou-Leurent
,
J. Dumortier
et al.
Journal articles
hal-01685801v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather
H. Fontaine
,
C. Hezode
,
F. Zoulim
,
D. Samuel
,
M. Bourlière
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S278, 2015,
⟨10.1016/S0168-8278(15)30182-3⟩
Conference poster
hal-01162770v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study
P. Houssel-Debry
,
C. Duvoux
,
A. Coilly
,
C. Fougerou-Leurent
,
C. Jezequel
et al.
Journal articles
hal-01533345v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Pegylated interferon α-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBsAg seroconversion
J.B. Costa
,
T. Dufeu-Duchesne
,
V. Leroy
,
I. Bertucci
,
M. Bouvier-Alias
et al.
Journal articles
hal-01427005v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study
T. M. Antonini
,
A. Coilly
,
S. Radenne
,
A. Veislinger
,
D. Botta-Fridlund
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S635--S636, 2015,
⟨10.1016/S0168-8278(15)31007-2⟩
Conference poster
hal-01162778v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial
M. Bourlière
,
P. Rabiega
,
N. Ganne-Carrie
,
L. Serfaty
,
P. Marcellin
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. pp.S249,
⟨10.1016/S0168-8278(15)30131-8⟩
Conference papers
hal-01162707v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More